Diagnostic-prognostic role of cytokines, interleukins, and biomarkers of early kidney injury in patients with ulcerous disease

Authors

  • G.V. Bachurin Zaporizhzhia State Medical University, Ukraine
  • Y.S. Kolomoets Zaporizhzhia State Medical University, Ukraine

DOI:

https://doi.org/10.26641/2307-5279.23.3.2019.178772

Keywords:

urolithiasis, acute and chronic pyelonephritis, chronic kidney disease, cytokines, interleukin, biomarkers of early kidney damage

Abstract

Urolithiasis - a metabolic disease caused by various endogenous and exogenous causes, is often hereditary and is determined by the presence of stone or stones in the urinary system. Purpose. Determination of the effectiveness of the use of cytokines, interleukin and biomarkers of early kidney damage in patients with urolithiasis in order to choose treatment and prevention tactics. Materials and methods. The study included 72 patients with urolithiasis who underwent an enzyme-linked immunosorbent assay of urine; among them the first group included 37 (51.4%) patients who underwent conservative therapy. In the second group - 32 (44.4%) patients who underwent endoscopic surgical treatment. In the third group - 3 (4.2%) patients who underwent treatment in the amount of open surgery. Results. In the analysis of the first group: an increase in all indicators was observed in 37.84%. The rate of creatinine and an increase in cytokines, interleukins and biomarkers of early kidney damage are 48.65%. The norm of all indicators is 10.81%. The rate of cytokines, interleukins, biomarkers and an increase in creatinine are 2.7%. In the analysis of the second group: an increase in all indicators was detected in 50%. The norm of creatinine and an increase in cytokines, interleukins, biomarkers - in 43.75%. All indicators were normal in 6.25%. When analyzing the third group: creatinine numbers were normal. An increase in cytokines, interleukins and biomarkers is 100%. Findings. The use of cytokines, interleukin and biomarkers of early damage to the kidneys, as a diagnostic criterion for the infectious and inflammatory process, is a valuable clinical tool for urolithiasis. An increase in cytokines, interleukin, and biomarkers indicates the presence of infectious and inflammatory complications before the onset of clinical and laboratory changes in almost 50% of cases. The introduction into clinical practice of cytokines, interleukin and biomarkers is a valuable criterion for the early detection and prevention of infectious and inflammatory complications in patients with urolithiasis.

References

Kamijo-Ikemori A., Ichikawa D., Matsui K. et al. Urinary L-type fatty acid binding protein (L-FABP) as a new urinary biomarker promulgated by the Ministry of Health, Labour and Welfare in Japan. Rinsho Byori. 2013. Vol. 96, No 61. Р. 635–640.

Ichimura et al. Kidney injury molecule-1 (KIM-1), a putativeepithelial cell adhesion molecule containing a novel immunoglobylindomain, is up-regulated in renal cells after injury. J. Biol. Chem. 1998. Vol. 273, No 7. P. 4135–4142.

Vaidya V.S., Bobadila N.A., Bonventre J.V. Urinary kidney injury molecule — 1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am. J. Physiol. Renal. Physiol. 2006. Vol. 290, No 2. P. 517–529.

Vaidya V.S., Ford G.M., Waikar S.S. et al. A rapid urine test for early detection of kidney injury. Kidney Int. 2009. Vol. 76, No 1. P. 108–114.

Han W.K., Bailly V., Bonventre J.V. Kidney injury molecule — 1 (KIM-1): a novel biomarker for human renal proximal tubular injury. Kidney Intern. 2002. Vol. 62, No 1. P. 237–244.

Femke Waanders M.D. et al. Effect of Renin-Angiotensin-Aldosterone System Inhibition, Dietary Sodium Restriction, and/or Diuretics on Urinary Kidney Injury Molecule 1 Excretion in Nondiabetic Proteinuric Kidney Disease: A Post Hoc Analysis of a Randomized Controlled Trial. Am. J. Kidney Dis. 2009. Vol. 53, No 1. Р. 16–25.

Jungbauer C.G., Birner C., Jung B. et al. Kidney injury molecule-1 and N-acetyl--D-glucosaminidase in chronic heart failure: possible biomarkers of cardiorenal syndrome. Eur. J. Heart Fail. 2011. Vol. 13, No 10. Р. 1104–1110.

Бережная Н.М., Чехун В.Ф. Система интерлейкинов и рак. Киев: ДИА, 2000. 224 с.

Кадагидзе З.Г. Цитокины и их использование в онкологии. Int. J. Reabilitation. 1997. № 6. С. 47–56.

Славина Е.Г. и др. Модуляция цитотоксического действия противоопухолевых лекарств in vitro интерфероном: связь с гиперэкспрессией генов mdr1 и bcl2. Аллергол. и иммунол. 2000. Т. 1, № 2. С. 170–171.

Тупицын Н.Н. Роль рецептора цитокинов gp 130 в росте и дифференцировке нормальных и опухолевых гемо поэтических клеток. Гематол. и трансфузиол. 2001. Т. 46. С. 9–14.

Фрейдлин И.С. Паракринные и аутокринные механизмы цитокиновой иммунорегуляции. Иммунология. 2001. № 5. С. 47.

Ярилин А.А. Система цитокинов и принципы ее функционирования в норме и патологии. Иммунология. 1997. № 5. С. 7–14.

Gracie J.A., Robertson S.E., McInnes I.B. Interleukin18. J. Leucocyte Biol. 2003. Vol. 73, No 2. P. 213–214.

Kishimoto T. The biology of IL6. Blood. 1989. Vol. 74, No 1. P. 110.

Lakour S., Hammann A., Wotava A. et al. Anticancer agents sensitize tumor cells to TNFrelated apoptosisinducing ligandmediated Caspase8 activation and apoptosis. Cancer Res. 2001. Vol. 61. P. 1645–1651.

Portielje J.E.A. et al. IL12: a promising adjuvant for cancer vaccination. Cancer Immunol. Immunother. 2003. Vol. 52. P. 133–144.

Tajima K. et al. Induction by IL5 of human killer cell activity against cancer cellines and its regulatory mechanisms. Human Pathol. 1998. Vol. 29, No 9. P. 1024–1028.

Weng N.P. et al. IL15 is growth factor and an activator of CD8 memory Tcells. Ann. N.Y. Acad. Sci. 2002. Vol. 975. P. 46–56.

Downloads

Published

2019-09-21

Issue

Vol. 23 No. 3 (2019)

Section

Сечокам'яна хвороба

License

Стаття повинна мати візу керівника та офіційне направлення від установи, з якої виходить стаття (з круглою печаткою), і вказівкою, чи є стаття дисертаційною, а також у довільній формі на окремому аркуші - відомості про авторів (прізвище, ім’я, по батькові, посада, вчений ступінь, місце роботи, адреса, контактні телефони, E-mail).

Стаття повина бути підписана всіма авторами, які укладають з редакцією договір пропередачу авторських прав (заповнюється на кожного автора окремо з оригінальним підписом). За таких умов редакція має право на її публікацію та розміщення на сайті видавництва.